An analysis of 18 randomized control trials comparing the effects of GLP-1 RAs, SGLT-2 inhibitors, and Metformin demonstrated that semaglutide, dapagliflozin, ipragliflozin, and canagliflozin showed a significant weight loss in comparison with placebo treated controls (6)
Potential Research Applications: Appetite control and satiety studies Blood glucose and insulin sensitivity research Obesity and metabolic syndrome models GLP-1 receptor pathway modulation investigations For laboratory research only
Zhang W, Chen Y, Yao Z, Ouyang M, Sun M, Zou S
Enhanced Energy Expenditure: Some studies suggest that Tirzepatide may also help increase energy expenditure, leading to more efficient calorie burning, which further contributes to weight loss